OCCIDENT’s portfolio company Tubulis raises more than €300 million
OCCIDENT participated in this incredible Series C round led by Venrock Healthcare Capital Partners to further develop antibody-drug conjugates (ADCs).
OCCIDENT
We invest in deep tech start-ups with a focus on spin-offs originating from
scientific research. What motivates us is having a real impact and enabling
concrete solutions for different challenges facing society today.
scientific research. What motivates us is having a real impact and enabling
concrete solutions for different challenges facing society today.
As a venture capital investor, we support start-ups from the seed stage onwards and enable founding teams to achieve outstanding results. With a strong entrepreneurial mindset, we invest our own money and make decisions based on sustainable potential for success.
Portfolio
Co-operation with the founding teams of our portfolio companies motivates and inspires us every day. We are energized by their passion and drive, and the often very intense exchange spurs us on to tackle challenges together.
Want to learn more about OCCIDENT?
OCCIDENT in numbers
Portfolio News
Thermosome reports encouraging data from Phase I trial
Early clinical data show encouraging efficacy and safety for THE001, supporting advancement into Phase 2 trials in advanced soft tissue sarcoma.
ReCatalyst establishes a strong Advisory Board
Four international industry experts will strengthen the company in the upcoming growth phase.
The Science Investor.
The OCCIDENT Team
Curious, perceptive, grounded and courageous, yet also humorous and team-oriented – that is the OCCIDENT team. As experts in our field, we know exactly what we are doing.
